Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases
Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases
复制标题
DOI：
10.1016/j.clcc.2018.08.004
复制
发表时间：
2019-03-01
影响因子：
3.4
通讯作者：
Sofocleous, Constantinos T.
中科院分区：
文献类型：
--
作者：
Kurilova, Ieva;Beets-Tan, Regina G. H.;Sofocleous, Constantinos T.
1年总生存预测诺模图包括6个易于获得的钇-90放射栓塞前参数，并提供了钇-90放射栓塞后总生存的良好预测。这可能是有用的预处理患者分层和大量预处理结直肠癌肝转移患者的咨询。基线最大标准化摄取值预测肝脏无进展生存期。引言：本研究的目的是确定对接受过大量预治疗的结直肠癌肝转移（CLM）患者进行钇-90放射性栓塞（RAE）后的总体（OS）和肝脏无进展生存期（LPFS）的预测因子，以及创建和验证OS的预测性列线图。材料和方法：分析了2009年9月15日至2017年3月21日期间接受RAE治疗的103例CLM患者的代谢、解剖、实验室、病理、遗传、原发疾病和手术相关因素，以及RAE治疗前后的情况。根据实体瘤疗效评价标准1.1和欧洲癌症研究和治疗组织标准定义LPFS。使用单变量考克斯回归选择OS和LPFS的预测因子，调整聚类和竞争风险分析（对于LPFS），随后在多变量分析（MVA）中进行检验。使用R统计软件构建诺模图，并使用bootstrap回归进行内部验证。结果：患者在检测到CLM后中位30.9个月（范围3.4-161.7个月）接受RAE。中位OS和LPFS分别为11.3个月（95%置信区间，7.9-15.1个月）和4个月（95%置信区间，3.3-4.8个月）。在40个参数中，有6个参数与MVA中的OS独立相关。这些基线参数包括肝外病变部位的数量（P
One-year overall survival prediction nomogram included 6 easy-to-obtain pre Yttrium-90 radioembolization parameters and provided good prediction of overall survival post Yttrium-90 radioembolization. This can be useful for pretreatment patient stratification and counseling of heavily pretreated patients with colorectal cancer liver metastases. Baseline maximum standardized uptake value predicted liver progression-free survival.Introduction: The purpose of this studywas to identify predictors of overall (OS) and liver progression-free survival (LPFS) following Yttrium-90 radioembolization (RAE) of heavily pretreated patients with colorectal cancer liver metastases (CLM), as well as to create and validate a predictive nomogramfor OS. Materials and Methods: Metabolic, anatomic, laboratory, pathologic, genetic, primary disease, and procedure-related factors, aswell as pre- and post-RAE therapies in 103 patients with CLM treated with RAE from September 15, 2009 to March 21, 2017 were analyzed. LPFS was defined by Response Evaluation Criteria In Solid Tumors 1.1 and European Organization for Research and Treatment of Cancer criteria. Prognosticators of OS and LPFS were selected using univariate Cox regression, adjusted for clustering and competing risk analysis (for LPFS), and subsequently tested in multivariate analysis (MVA). The nomogram was built using R statistical software and internally validated using bootstrap resampling. Results: Patients received RAE at a median of 30.9 months (range, 3.4-161.7 months) after detection of CLM. The median OS and LPFS were 11.3 months (95% confidence interval, 7.9-15.1 months) and 4 months (95% confidence interval, 3.3-4.8 months), respectively. Of the 40 parameters tested, 6 were independently associatedwithOS inMVA. These baseline parameters included number of extrahepatic disease sites (P